Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates

Marcel A Behr; Maziar Divangahi; Erwin Schurr

doi:10.1093/infdis/jiaa637

Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates

J Infect Dis. 2021 Feb 3;223(2):189-191. doi: 10.1093/infdis/jiaa637.

Authors

Marcel A Behr^{1

2

3

4}, Maziar Divangahi^{1

2

4

5}, Erwin Schurr^{1

2

3

4}

Affiliations

¹ Department of Medicine, McGill University, Montreal, Quebec, Canada.
² McGill International TB Centre, Montreal, Quebec, Canada.
³ Infectious Diseases and Immunity in Global Health, McGill University Health Centre Research Institute, Montreal, Quebec, Canada.
⁴ McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Quebec, Canada.
⁵ Meakins-Christie Laboratories, Montreal, Quebec, Canada.

Abstract

Developers of severe acute respiratory syndrome coronavirus 2 vaccines should consider some of the lessons from a "new" vaccine introduced in 1921, namely bacille Calmette-Guérin.

Keywords: BCG; COVID-19; SARS-CoV-2; vaccine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
BCG Vaccine / administration & dosage
BCG Vaccine / immunology*
COVID-19 / immunology
COVID-19 / prevention & control*
COVID-19 / virology
COVID-19 Vaccines / administration & dosage
COVID-19 Vaccines / immunology*
Humans
Pandemics / prevention & control
Randomized Controlled Trials as Topic
SARS-CoV-2 / immunology*
Tuberculosis / immunology
Tuberculosis / prevention & control

Substances

BCG Vaccine
COVID-19 Vaccines